Articles tagged with Tumor Cells
Researchers at Pusan National University have developed a novel drug delivery system that uses nanoparticles to target and kill colorectal cancer cells. The system, which involves encapsulating cancer cell-activated nanoconjugates in an alginate matrix, can selectively deliver drugs to tumor cells while minimizing side effects.
A new nanomedicine, ZnDHT NM, selectively targets cancer stem-like cells (CSCs) and tumor cells, promoting CSC differentiation while inhibiting EMT. This approach also leads to the release of toxic compounds in tumor cells, inducing apoptosis/ferroptosis pathways.
A team of international researchers found that tumor cells become drastically diverse when exiting the bone marrow, affecting immune cells in the cancer lesions. This discovery could contribute to more precise diagnostics and therapy for multiple myeloma, a incurable bone marrow cancer.
A potential new therapy, CT-179, effectively targets tumor cells and disrupts cancer stem cells, leading to improved treatments and increased survival rates. The novel drug, developed by Curtana Pharmaceuticals, may bring new efficacy to brain tumor therapy.
The team's novel technique enables high-throughput screening of nanoparticle shapes, sizes, and modifications, reducing associated screening costs. The research demonstrates the distinct preferences of tumour cells for certain nanoparticle configurations, enabling personalized cancer treatments that are safer and more effective.
Researchers tracked cfDNA levels before, during, and after colorectal cancer surgery, revealing significant increases associated with age, comorbidities, and surgical manipulation. The study suggests that cfDNA could serve as a non-invasive biomarker to monitor patient outcomes and evaluate surgical effectiveness.
Researchers have discovered a key strategy through which persister cells evade the immune response and resist cancer treatments. Inhibiting an epigenetic mechanism could unlock inflammatory genes and compromise persister cell viability.
Researchers developed a new super-resolution microscopic method to investigate the interactions of therapeutic antibodies with target molecules on tumour cells. The study reveals that all four antibodies crosslink CD20 molecules independently of type I or II classification, and that B cells take on a hedgehog shape after treatment.
Researchers at the University of Alabama at Birmingham have identified HIF1α as a key regulator that induces cancer-killing capacity in T cells under hypoxic conditions. In this study, they found that HIF1α-glycolysis is indispensable for IFN-γ induction in hypoxic T cells.
Researchers at TUM have grown tumor organoids that reproduce the morphological complexity of pancreatic cancer cells in the laboratory. The team used machine learning to categorize the organoids into different phenotypes based on their appearance and behavior, which react differently to treatments.
Researchers aim to improve treatment response in patients with clear cell renal cell carcinoma by reprogramming tumor cells into immune cells that recognize and kill cancer cells. This approach combines checkpoint inhibitors to enhance the immune response.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a new genetic code that recruits and deploys tumor cells to invade healthy organs. This breakthrough could offer groundbreaking insight into new treatment strategies targeting tumor growth in its earliest stages.
Researchers found that tumor cell secreted DNA in extracellular vesicles acts as a 'danger' signal to activate an anti-tumor response in the liver, reducing liver metastasis risk. The discovery improves understanding of cancer progression and anticancer immunity.
Researchers develop a method to remove copper from tumor cells, killing them. The nanofibers use copper-binding domains to grasp copper ions, disrupting cellular homeostasis and increasing oxidative stress.
Researchers at University of California - San Francisco designed biological sensors that can ensure engineered cells are activated in tumor environments, making cancer therapies more effective. The new sensors, called SNIPRs, can bind to soluble molecules and alter gene expression, offering a promising approach for targeted therapies.
A new mathematical model of prostate cancer has been developed, revealing key findings on genetic changes and tumour growth. The study shows that strong genetic changes are necessary for aggressive tumours to develop early in the course of tumour development.
The review explores the impact of extracellular matrix (ECM) geometry on immune cell behavior and treatment efficacy. Specific ECM configurations, known as Tumor-Associated Collagen Signatures (TACS), create physical barriers that limit immune cell access to tumors.
A new strategy for treating prostate cancer has been developed by blocking the GP130 signalling pathway, contrary to current medical understanding. The study found that activating GP130 in prostate cells reduces tumour growth and stimulates the immune system to fight cancer cells.
Researchers at MIT have designed tiny particles that can be implanted at a tumor site, delivering heat and chemotherapy to treat cancer. The treatment approach has been shown to completely eliminate tumors in most mice and prolong their survival.
A new study from the University of Texas at Arlington suggests that analyzing RNA in urine can show changes in cell types, revealing early signs of cancer and other diseases. This method could help clinicians detect problems earlier when they are more easily treated without invasive procedures.
Researchers created a 3D-printed model to mimic the conditions that spur cancer cells' spread, allowing them to visualize this process in real-time. The model revealed a mechanism where low oxygen levels promote metastasis through lowering pH levels.
Researchers found Edaravone inhibits growth of brain tumor stem cells and prolongs survival in mice with glioblastoma. The study suggests repurposing Edaravone as a potential treatment for this aggressive brain cancer.
Research discovered that chloride ion channels play a role in glioblastoma cell division and proliferation. By blocking these channels, replication can be stopped, pointing to ion currents as a potential target for therapeutic approaches.
A new study has found that using a higher dosage of radioembolisation treatment with yttrium-90 microspheres can improve overall survival outcomes for liver cancer patients. Patients who received this elevated dose had significantly better results, with some experiencing prolonged survival and even curative treatments.
Researchers at UNIGE and HUG have developed CAR-T cells capable of targeting malignant gliomas while sparing healthy tissue. The treatment uses a specific marker on tumour cells and appears to be effective in controlling tumour growth without signs of toxicity.
Researchers discovered a key molecule, PAF, that controls the destiny of immune cells and turns them against cancer. The study highlights the importance of targeting PAF to develop new therapies for various types of cancer.
Researchers have successfully visualized and tracked specific cells in deep brain tissue, including along the corpus callosum's nerve fibre highway. This advancement could potentially lead to better diagnostic tools for glioblastoma, a deadly brain cancer.
Researchers at Johns Hopkins Medicine found that age-related changes in male fibroblasts contribute to more aggressive and treatment-resistant melanomas. The study discovered that male fibroblasts accumulate reactive oxygen species and produce higher levels of BMP2, leading to increased DNA damage and resistance to targeted therapies.
Researchers have discovered that sodium chloride can increase the efficiency of antitumoral T cells, leading to improved metabolic fitness and enhanced tumor killing capabilities. This finding has significant implications for adoptive T-cell therapy in cancer treatment.
A new study by UCLA investigators found that Manuka honey contains compounds that can help reduce tumor growth in preclinical models. The research suggests that Manuka honey could potentially be developed into a natural supplement or standalone treatment for ER-positive breast cancer, which accounts for most breast cancer cases.
A Rice University-led team is developing an affordable system to improve tumor removal accuracy for breast and head and neck cancer. The AccessPath system enables rapid, automatic tumor margin classification, revolutionizing real-time surgical guidance.
Researchers developed a new approach to combat cancer by hyperactivating tumor cells, making them stressed and vulnerable to specific drugs. The combination strategy showed promising results in colorectal and pancreatic adenocarcinoma models, paving the way for potential treatment options.
Researchers explore various immunotherapies, including immune checkpoint inhibitors and adoptive cell therapies, as promising treatments for hepatocellular carcinoma. The review aims to overcome current limitations of targeted therapies by regulating the body's immune systems.
Researchers at UCLA Health Jonsson Comprehensive Cancer Center discovered that the protein IRF1 can both hinder and help the body's immune response to tumors, depending on which cells it is found in. The study suggests that targeting IRF1 could enhance cancer treatment effectiveness by boosting natural antitumor immunity.
Researchers identify key proteins and signaling pathways for personalized treatment, enabling early detection of aggressive tumors. The study provides a crucial resource for developing new therapies and tests to guide treatment.
Researchers at CeMM have identified a synthetic variant inspired by the Withanolides group that acts highly specifically against leukemia cells. The molecule disrupts the cholesterol metabolism of tumor cells.
Researchers created nanomicelles containing substances already approved for human use, which reduced inflammation in the tumor microenvironment and facilitated the action of the immune system. The treatment induced a reduction of over five times in tumor volume compared to untreated tumors.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers explore nanoparticle-based therapies to specifically target lymphatic metastasis in breast cancer, providing a promising solution for patient treatment. Nanoparticles deliver drugs directly to tumors, targeting cancer cells to destroy them or slow their growth, while also enhancing the immune response.
Researchers found that GZ17-6.02 killed uveal melanoma cells by enhancing autophagy, inactivating key proteins, and reducing growth factors. The compound also interacted with doxorubicin and ERBB inhibitors to enhance tumor cell killing, suggesting potential as a single agent or combination therapy.
Researchers found that blocking PI3K-beta makes glioblastoma cells more sensitive to temozolomide treatment, slowing down tumor growth. The study's findings could lead to new treatments for patients with chemotherapy-resistant glioblastoma.
A new study published in Nature Biomedical Engineering shows that targeted cancer treatment using antibody-displaying extracellular vesicles reduces tumour growth and improves survival in mice. The treatment has the potential to be used against other diseases and cancer types, offering a more effective and fewer side effects compared t...
Researchers identified EHF as a critical transcription factor in cholangiocarcinoma development through activation of GLI1 and CCL2. Targeted therapies targeting these pathways showed promise in inhibiting tumor growth and infiltration.
Glioblastoma cancer cells change their appearance and behavior to evade T-cell attack, rendering immunotherapy ineffective. Researchers found that these 'plastic' cells can also exhaust T-cells, making glioblastoma resistant to treatment.
Researchers have identified a novel protein FOXF1 that stabilizes blood vessels inside lung tumors, decreasing intertumoral hypoxia and preventing lung cancer metastases. Increasing levels of FOXF1 or FZD4 shows promise to improve therapeutic outcomes in lung cancer patients.
A microfluidic device separates single tumor cells, tumor cell clusters, and white blood cells from clinical pleural or abdominal effusions. The technology recovers over 97% of tumor cells and preserves 90% of vital tumor cell clusters.
Researchers at the University of Oklahoma have discovered how pancreatic cancer cells exploit an acidic environment to their advantage, finding ways to survive and grow. This knowledge is crucial for developing new therapeutic approaches to target the cancer.
A large trial enrolling nearly 2,800 patients from five countries has clarified the situation for patients with larger metastases. The study found that leaving most of the lymph nodes intact resulted in similar recurrence rates as completion axillary dissection, but with fewer arm-related complications.
Researchers developed an AI model to detect viable tumor cells in osteosarcoma patients, improving prognosis predictions. The model showed comparable detection performance to pathologists and reduced inter-assessor variability, enabling timely assessment.
Researchers unveil innovative strategies to overcome metabolic constraints in CAR-T cell therapy, aiming to boost its efficacy in treating solid tumors. Metabolic interventions targeting immunosuppressive metabolites, metabolite uptake, and mitochondrial metabolism are proposed to enhance anti-tumor activity.
A new study suggests that tailored treatment can predict the response of breast cancer patients to chemotherapy, allowing for safe omission of extensive lymph node removal. The MARI protocol showed a 95% overall survival rate and 89% disease-free survival rate in patients who achieved pathological complete response.
A UNIGE team has identified the mechanism of action of PARP inhibitors, used to treat breast and ovarian cancer. By blocking one activity while preserving another, these inhibitors can maintain toxic effects on cancer cells while sparing healthy cells.
A research team at the University of Cologne has identified mechanisms governing drug response in small cell lung cancer. The study reveals that large populations of treatment-sensitive cells often hide numerous therapy-resistant cells that can multiply unchecked after successful treatment.
Researchers discovered GZ17-6.02's ability to interact with proteasome inhibitors in a greater than additive fashion to kill multiple myeloma cells and alone inhibit inhibitor-resistant cells. The compound combination also activated key pathways and increased autophagosome formation, leading to tumor cell killing.
A new nanocarrier has been developed that can selectively release drugs in cancer cells through controlled endosomal escape. The approach exploits the unique enzymatic activity of cancer cells, allowing for targeted delivery and reduced harm to healthy cells.
Researchers found GZ17-6.02 alone and in combination with standard-of-care agents was effective in killing MF cells, activating key pathways including ATM, AMPK, NFκB, and macroautophagy. The compound's unique multi-factorial mechanism suggests potential for treating mycosis fungoides.
A novel chemotherapy approach uses patient's own cells as Trojan horses to deliver targeted cancer-killing drugs to lung cancer cells. The method has shown promise in reducing tumor size and improving treatment efficacy with minimal collateral damage to healthy tissues.
Researchers develop a new strategy to make CAR T cell therapy more effective and safer by targeting multiple surface proteins on malignant tumour cells. The approach shows promise in fighting cancer cells while sparing healthy B lymphocytes.
A novel reporter cell experimental system enables the visualization of sequential changes during endothelial-mesenchymal transition (EndoMT) induced by transforming growth factor-β. Researchers identified CD40 as a potential partial EndoMT marker, which suppresses the transition from partial to full EndoMT.
Researchers found that artepillin C interacts intensely with tumor cells, altering their fluidity and triggering autophagy. The study's results contribute to a deeper understanding of the substance's action mechanisms and provide insights for future research.